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Although used mainly for transplantation of hematopoietic stem cells in the treatment of blood disorders,
umbilical cord blood (UCB)-based therapies are now being used increasingly for novel applications in non-
hematopoietic diseases and as a form of cellular regenerative therapy or immune modulation. We performed
a systematic scoping review by searching Medline, EMBASE, and the Cochrane Library for published articles,
and we searched www.clinicaltrials.com and the World Health Organization International Clinical Trials
Registry Platform to describe the breadth of published studies and ongoing clinical activity in umbilical cord-
based cellular therapy for regenerative therapy and immune modulation. The most commonly published area
of expertise in the use of UCB-derived cellular transplantation for novel indications is for neurological
disorders and this remains the most active area of study in ongoing registered trials. An increasingly broad
range of disorders, however, are reﬂected in ongoing registered trials, which suggests greater activity,
interest, and investment in UCB-derived cellular therapy. Interestingly, adult patients compose the majority of
patients reported in published reports and registered ongoing clinical studies continue to enroll predomi-
nantly adult subjects. Geographically, Asian countries appear most active in UCB-derived cellular therapy and
our analysis of ongoing studies suggests this trend will likely continue. Regular assessment of published and
ongoing activity in UCB transplantation for emerging novel indications will be critical for informing UCB
banking establishments and funding agencies to guide changes in banking practices related to emerging
trends in cell therapy.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION in many parts of the world [13], providing easy access to UCB
Transplantation of cells derived from human umbilical
cord blood (UCB) has demonstrated increasing promise in
the treatment of both malignant and nonmalignant diseases
[1-3]. Following the ﬁrst successful transplantation of UCB in
1988 for the treatment of Fanconi’s anemia [4], the past
decades have led to increased use of cord blood as a source of
cells for hematopoietic stem cell transplantation to treat
a range of hematological and nonhematolgioical diseases [5].
UCB also contains nonhematopoietic stem and progenitor
cells capable of differentiating into epithelial [6] or endo-
thelial cell progenitors [7,8], mesenchymal stromal cells
(MSCs), unrestricted somatic stem cells [9], and neural
progenitor cells [10]. The therapeutic potential of stem and
progenitor cells in UCB to treat a broad range of disorders has
led to increasing use of UCB transplantation to treat patients
with nonhematopoietic diseases, including applications in
regenerative therapy and modulation of refractory autoim-
mune diseases.
UCB cells can be cryopreserved and stored for years
without signiﬁcant loss of viability, making them readily
available for immediate transplantation in most instances
[11,12]. Public banking of UCB has become more widespreadedgments on page 24.
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13.09.010units fromworldwide registries [12]. Private banking of cord
blood is also available in many jurisdictions. The increased
demand for UCB banking has led to the development of
regulatory bodies for quality control, including the American
Association of Blood Banks and the Foundation for Accredi-
tation of Cellular Therapy [14,15].
Although used mainly for transplantation of hematopoi-
etic stem cells in the treatment of blood disorders, UCB-
based therapies are now being used increasingly for novel
applications in nonhematopoietic diseases and as a form of
cellular regenerative therapy or immune modulation. In this
systematic scoping review, we describe the breadth of pub-
lished studies and ongoing clinical activity in umbilical cord-
based cellular therapy for regenerative therapy and immune
modulation. Our primary goal was to identify current trends
in cell-based therapy using UCB that would inform cord
blood banking establishments and transplantation centers
regarding current and emerging trends related tomethods of
cell manipulation and indications for using cord blood in
regenerative medicine and immune modulation.
MATERIALS AND METHODS
Searching for Relevant Published Trials
We sought to identify studies that described the use of human UCB to
treat patients for nonconventional indications that addressed regenerative
therapy or modulation of immune disorders. A systematic scoping review of
all published trials was performed in accordance with guidelines suggested
by the Preferred Reporting Items for Systematic Reviews andMeta-Analyses
[16]. We performed a search on the following databases using the OVID
interface: (1) MEDLINE (1950 to week 26 of 2012), (2) EMBASE (1980 toTransplantation.
Search Strategy:
--------------------------------------------------------------------------------
1 Fetal Blood/cy, tr (5693)
2 fetal blood/ and Hematopoietic Stem Cell Transplantation/ (1115)
3 Cord Blood Stem Cell Transplantation/ (1875)
4 uc blood.tw. (50)
5 (umbilical adj2 blood).tw. (8402)
6 (cord adj2 blood).tw. (19258)
7 (placenta$ blood adj2 transplant$).tw. (17)
8 or/1-7 (22852)
9 Regenerative Medicine/ (2141)
10 exp Regeneration/ (157579)
11 regener$.tw. (104758)
12 Basilar Artery/su or (basilar adj2 arter$ dissection$).tw. (505)
13 Ischemia/ or (Limb$ adj2 ischemia$).tw. (44373)
14 Cardiomyopathy, Dilated/ or (congestive adj2 cardiomyopath$).tw. or (familial idiopath$ adj2 cardiomyopath$).tw. or 
(cardiomyopath$ adj2 dilat$).tw. (17665)
15 Hypoplastic Left Heart Syndrome/ or (hypoplasti$ adj3 left heart syndrome$).tw. (2051)
16 Diabetic Foot/ or (diabet$ adj3 foot$).tw. or (diabet$ adj3 feet$).tw. (7001)
17 Spinal Cord Injuries/ or (spinal cord adj3 contusion$).tw. or (spinal cord adj3 injur$).tw. or (spinal cord adj3 
trauma$).tw. or (spinal cord adj3 laceration$).tw. or (myelopath$ adj3 post-traumatic).tw. or (myelopath$ adj3 
posttraumatic).tw. or (traumatic adj3 myelopath$).tw. or (spinal cord adj3 transection$).tw. (33613)
18 Cerebral Palsy/ or cerebral pals$.tw. or (diplegia$ adj2 spastic).tw. or little$ disease.tw. (18522)
19 Cerebellar Ataxia/ or (Incoordination$ adj3 cerebellar).tw. or Adiadochokin$.tw. or Hypermetria$.tw. or (Ataxia$ adj3 
cerebellar).tw. or (cerebellar adj2 hemiataxia$).tw. or dysmetria$.tw. (6336)
20 Brain Injuries/ or (encephalopath$ adj3 post concussive).tw. or (traumatic adj3 encephalopath$).tw. or (brain adj3 
laceration$).tw. or (trauma$ adj3 brain).tw. or (injur$ adj3 brain).tw. or (contusion$ adj3 brain).tw. or (cortical adj3 
contusion$).tw. (57956)
21 Hypoxia-Ischemia, Brain/ or (Anoxi$ adj3 ischemia$).tw. or (hypoxi$ adj3 ischemi$).tw. (9085)
22 Brain Ischemia/ or Stroke/ or (Encephalopath$ adj3 ischemi$).tw. or (Ischemia$ adj3 cerebral).tw. or (Brain adj3 
ischemi$).tw. or (chronic ischemi$ adj3 stroke).tw. (89138)
23 Amyotrophic Lateral Sclerosis/ or (disease adj2 guam).tw. or (Gehrig$ adj2 disease$).tw. or (amyotrophic adj4 lateral 
sclerosis).tw. or als.tw. or motor neuron disease.tw. (21881)
24 Diabetes Mellitus, Type 1/ or (Autoimmun$ adj3 diabet$).tw. or (Diabete$ mellitus adj4 sudden onset).tw. or 
(Diabete$ mellitus adj4 brittle).tw. or iddm.tw. or (diabetes mellitus adj5 insulin dependent).tw. or (ketosis prone adj4 
diabetes mellitus).tw. or (juvenile onset adj5 diabete$ mellitus).tw. or (type 1 adj4 diabete$).tw. (72905)
25 Liver Cirrhosis/ or (Fibros$ adj3 liver).tw. or (Cirrhos$ adj2 hepatic).tw. or (Cirrhos$ adj2 liver).tw. (66791)
26 Thromboangiitis Obliterans/ or (Buerger$ adj2 disease$).tw. or thromboangitis obliterans.tw. (2841)
27 exp Eye Diseases/ or ocular surface disease$.tw. or ocular surface disorder$.tw. or asthenopia.tw. or cogan 
syndrome$.tw. or conjunctival disease$.tw. or corneal disease$.tw. (425213)
28 exp Hearing loss/ or Acquired hearing loss.tw. (51193)
29 Infant, Premature/ or premature$ infan$.tw. or preterm infan$.tw. or extremely low birth weight$.tw. (50626)
30 or/9-29 (1140445)
31 8 and 30 (2366)
32 clinical trial.pt. (476541)
33 exp clinical trial/ (705850)
34 randomized controlled trial.pt. (342317)
35 controlled clinical trial.pt. (85680)
36 randomi?ed.ab. (309312)
37 placebo.ab. (141651)
38 trial.ti. (111077)
39 exp Clinical Trials as Topic/ (264111)
40 multicenter study.pt. (152981)
41 exp epidemiologic studies/ (1487306)
42 (cohort adj2 (study or analysis)).tw. (72043)
43 (case adj2 (control$ or series or report$)).tw. (400611)
44 case reports.pt. (1609515)
45 or/32-44 (3879201)
46 31 and 45 (471)
47 animals/ not humans/ (3717560)
48 46 not 47 (451)
49 limit 48 to yr="1860 - 2012" (451)
50 ("20120726" or "20120727" or "20120728" or "20120729" or "20120730" or "20120731" or 201208$ or 201209$ or 
201210$ or 201211$).ed. (460226)
51 49 not 50 (434)
Figure 1. Search Strategy used in Ovid MEDLINE(R) In-Process and Other Nonindexed Citations and Ovid MEDLINE(R), 1946 to present; limited to July 25, 2012.
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Medline - 434
EMBASE - 530
Cochrane - 0
273 duplicates removed
691 articles considered
671 non-relevant articles
25 articles retrieved for full review
20 articles met inclusion criteria
5 articles excluded:1 
duplicate publication, 1 
study in mice, 1 study of 
indication deemed a 
standard indication for 
UCBT, 1 abstract had 
insufficient data, and 1 
study used acellular
components of cord blood
4 further articles identified 
from reviews and experts
Figure 2. Summary of results from the systematic search strategy and iden-
tiﬁcation of studies included for analysis.
M.A.J. Iafolla et al. / Biol Blood Marrow Transplant 20 (2014) 20e2522week 26 of 2012), and (3) Cochrane (1950 to the second quarter of 2012),
using the search strategy detailed in Figure 1. Speciﬁcally, the following
search concepts were used: (1) umbilical cord transplantation, (2) regen-
erative medicine, and (3) speciﬁc diseases associated with potential success
with UCB. To further augment our search, we attempted to identify any
potential “grey” literature using Google Scholar. Reference lists of included
studies were reviewed to identify additional published material. To identify
ongoing registered clinical studies, the website www.clinicaltrials.gov and
the search portal of the World Health Organization’s International Clinical
Trials Registry Platform (ICTRP) at http://www.who.int/ictrp/search/en/
were searched using broad terms for umbilical cord blood, infusion, and
transplantation (performed March 1, 2013).Information Analysis
All duplicates, editorials and opinion articles, review articles, studies
involving animals, and articles that did not involve human UCB were
removed. The process of selecting articles for inclusion and subsequent
analysis was performed in duplicate (M.A.J.I. and D.S.A.). All relevant studies
were ﬁrst divided into published clinical trials or ongoing clinical trials, then
further categorized based on disease process (ie, cardiovascular, diabetes,
hepatic, etc.). Each paper was then analyzed for the following parameters:
speciﬁc disease treated, patient age, geographic region of intervention,
whether the cord blood units were banked in private or public establish-
ments, relationship of patient to donor of banked cord blood unit (allogeneic
or autologous), the route of administration of cells to the patient, and cell
type and quantity (ie, total nucleated cells, MSCs, or other). These parame-
ters were then tabulated and described.RESULTS
Our search for published literature on clinical use of UCB
for nonhematologic indications yielded a total of 691 publi-
cations after removing duplicates and excluding editorials,
opinion articles, studies involving animals, and articles that
did not involve human UCB (see Figure 2). In addition, arti-
cles describing the use of cord blood transplantation for
hematopoietic disorders or inherited metabolic disorders
were excluded, as these papers addressed accepted and/or
standard indications for transplantation. A total of 25 articles
were selected for full review and 5 articles were subse-
quently excluded on the basis of duplicate publication (1
study), standard indication for UCB transplantation (1 study
describing X-linked chronic granulomatous disease),
nonhuman transplant model (1 study), insufﬁcient reporting
of data (1 abstract), and the use of acellular components of
cord blood (1 study). A total of 20 published articles
describing the treatment of 317 patients, therefore, were
included in our ﬁnal analysis. Three of the studies were
controlled (nonrandomized) [17-19], including a total of 115
patients (controls are not included in the patient totals for
the studies described in Table 1). The most widely reportedactivity was the use of UCB-derived cells to treat neurological
disorders [20-28] (total of 156 patients in 9 published
studies), liver cirrhosis and hepatitis [17,19] (99 patients in 2
studies), and type 1 diabetes [18,29] (30 patients in 2
studies). A complete list of disorders described in published
reports is provided in Table 1. In some cases, the UCB-derived
cells were infused with the intent to repair damaged tissues
[17,19-28,30-33] (15 studies, 260 patients), whereas in other
patients, the cells were intended to facilitate immune
modulation [18,29,34-36] (5 studies, 57 patients). Only 3
published reports had control groups (case controls or
control groups in randomized trials) describing a total of 114
treated patients. Although the safety and feasibility of infu-
sionwere described inmost reports, data suggesting possible
clinical beneﬁt were described in 15 studies reporting on
outcomes of 179 treated patients. Possible beneﬁt was re-
ported in at least 1 report for each of the disease categories
(see Table 1). Patient-speciﬁc data extraction was not per-
formed and pooled analysis of data was not possible because
of lack of controls and/or heterogeneity of the studies.
Our preliminary search of registered clinical studies
revealed a total of 411 studies from www.clinicaltrials.com
and 93 studies from the World Health Organization’s ICTRP.
After removing duplicates and screening for relevance, we
identiﬁed a total of 47 ongoing registered clinical trials that
address a wider spectrum of novel clinical indications for
UCB-derived cell therapy (see Table 1 for complete list of
studies). Within this group of 47 studies, 9 appeared in both
registries. There is apparent increased activity in the use of
UCB-derived cells for the treatment of neurological disorders
(23 trials), with a total of 9 trials enrolling patients with
cerebral palsy. Other ongoing trials reﬂect increased activity
in the treatment of type 1 diabetes (7 trials) and liver
cirrhosis (7 trials). The majority of ongoing trials address
regenerative therapy (35 studies) as opposed to immuno-
modulatory therapy for autoimmune conditions (12 studies).
The result of our search for ongoing studies using UCB-
derived cells for regenerative therapy or immune modula-
tion is provided in Table 1.
The majority of published and active trials involve adult
patients or a combination of adult and pediatric patients,
with only 7 published studies [22,24,27-29,32,33] (46
patients) and 17 ongoing studies enrolling only pediatric
patients. (Table 2) Most patients described in published
reports were treated in China [17,19,23,25,28,32,33,36] (8
studies, 261 patients), the United States [18,21,29,30] (4
studies, 32 patients), and Korea [20,24,34,35] (4 studies, 13
patients). Other countries that have published their obser-
vations of patients undergoing UCB-derived regenerative or
immunomodulatory therapy are European countries [26,31]
(2 studies involving 3 patients), Russia [22] (1 study
involving 6 patients), and Thailand [27] (1 study involving 2
patients). Ongoing registered studies reﬂect a similar
geographic distribution with the majority of registered
studies coming from China (26 studies), the United States (9
studies), and Korea (6 studies). (Table 3)
Themost common cell type described in published articles
of UCB transplants is the administration of total nucleated
cells, mononuclear cells, or CD34-selected hematopoietic
progenitors [19,22,23,25-27,29,31,32,34] (10 studies, 227
patients), given either intravenously [19,22,23,26,27,29,32] (7
studies,104 patients) or through intrathecal, subcutaneous, or
intramuscular injection [25,31,34] (3 studies, 123 patients).
MSCs or expanded adherent cells cultured ex vivo were
infused intravenously in 5 published studies [17,18,28,33,36]
Table 1
Clinical Studies of Regenerative Therapy or Modulation of Refractory Autoimmune Disease Using Umbilical Cord BloodeDerived Cell Transplantation
Disease Categories Published Studies Registered Ongoing
Studies
Published
(Patients)
Controlled
Studies (Patients)
No. Reporting Possible
Beneﬁt (Patients)
n
Neurological 9 (156) 0 6 (40) 23
Spinal cord injury [20,21]* 2 (2) 0 2 (2) 3
Traumatic brain injury [22]y 1 (6) 0 1 (6) 4
Stroke [23,24]z 2 (11) 0 1 (10) 3
Neurodegenerative disorders [25,26]x 2 (115) 0 0 2
Cerebral palsy, neonatal hypoxic-ischemic encephalopathy,
and global developmental delay [27,28]k
2 (22) 0 2 (22) 9
Autism{ 0 1
Preterm neonates# 0 1
Diabetes mellitus 2 (30) 1 (15) 1 (15) 8
Type 1 diabetes mellitus [18,29]** 2 (30) 1 (15) 1 (15) 7
Type 2 diabetesyy 0 1
Cardiac and vascular 3 (12) 0 2 (5) 3
Thromboangiitis obliterans [34,35] 2 (11) 0 1 (4) 0
Critical limb ischemiazz 0 1
Hypoplastic left heart syndromexx 0 1
Idiopathic dilated cardiomyopathy [30],kk 1 (1) 0 1 (1) 1
Hepatic/gastrointestinal 2 (99) 2 (99) 2 (99) 9
Liver cirrhosis [17],{{ 1 (30) 1 (30) 1 (30) 7
Viral hepatitis [19],## 1 (69) 1 (69) 1 (69) 1
Ulcerative colitis*** 0 1
Dermatological 1 (2) 0 1 (2) 2
Skin wound [31], burnyyy 1 (2) 0 1 (2) 1
Epidermolysis bullosazzz 0 1
Other 3 (18) 0 3 (18) 2
Rheumatoid arthritisxxx 0 1
Systemic lupus erythematosus [36],kkk 1 (16) 0 1 (16) 1
Duchenne muscular dystrophy [32,33] 2 (2) 0 2 (2) 0
Total 20 (317) 3 (114) 15 (179) 47
* NCT01046786, NCT01393977, NCT01471613.
y NCT01251003, NCT01451528, NCT01649648, ChiCTR-TNRC-11001528.
z NCT01438593, NCT01673932, NCT01700166.
x NCT01489267, NCT01494480.
k NCT00593242, NCT01072370, NCT01147653, NCT01193660, NCT01506258, NCT01528436, NCT01601158, NCT01649648, ChiCTR-TNC-11001486.
{ NCT01343511.
# NCT01121328.
** NCT00305344, NCT00873925, NCT00989547, NCT01143168, NCT01219465, NCT01374854, ACTRN12613000186752.
yy NCT01413035.
zz NCT00518934.
xx NCT01445041.
kk NCT01739777.
{{ NCT1220492, NCT01224327, NCT01491165, NCT01342250, NCT01573923, NCT01718587, ChiCTR-TNRC-11001488.
## NCT01724398.
*** NCT01221428.
yyy NCT01443689.
zzz NCT01033552.
xxx NCT01547091.
kkk NCT01741857.
M.A.J. Iafolla et al. / Biol Blood Marrow Transplant 20 (2014) 20e25 23(82 patients) or given through intrathecal or intramuscular
injection [20,24,35] (3 studies, 6 patients), whereas combined
therapy using CD34-selected cells with MSCs expanded from
UCB was described in 2 case reports [21,30] (2 patients) using
either intravenous infusion [30] (1 patient) or intrathecal
injection [21] (1 patient). (Table 4) The majority of published
studies describe the use of cord bloodederived cells from
allogeneic sources (18 studies, 300 patients), whereas only 2Table 2
Populations Treated with UCB Stem Cells
Patient Population Published (Patients) Ongoing Studies, n
Pediatric 7 (46) 17
Adult 11 (142) 24
Pediatric and adult 2 (129) 6
UCB indicates umbilical cord blood.studies [27,29] (10% of studies; 17 patients, or 5.4% of patients)
used autologous cells. Ongoing registered clinical trials,
however, describe increasing use of autologous cells (13
studies, or 28% of registered studies).
DISCUSSION
Analysis of the published literature and ongoing registered
clinical studies reveals a broad range of diseases treated with
UCB-derived cellular products. The most commonly pub-
lished area of expertise in the use of UCB-derived cellular
transplantation for regenerative and immunomodulatory
therapy is for neurological disorders, and this remains the
most active area of study in ongoing registered trials. An
increasing range of disorders, however, is reﬂected in the
ongoing registered trials, which suggests increasing activity,
interest, and investment in UCB-derived cellular therapy.
Interestingly, adult patients compose the majority of patients
Table 3
Geographic Regions Treated with UCB Stem Cells
Geographic Region Published
(Patients)
Ongoing
Studies, n
China 8 (261) 26
United States 4 (32) 9
Korea 4 (13) 6
European Union þ United Kingdom 2 (3) 1
Thailand 1 (2) 0
Russia 1 (6) 0
Egypt 0 1
Mexico 0 1
Singapore 0 1
South America 0 1
Australia 0 1
UCB indicates umbilical cord blood.
M.A.J. Iafolla et al. / Biol Blood Marrow Transplant 20 (2014) 20e2524reported in published reports and registered ongoing clinical
studies continue to enroll predominantly adult subjects.
Geographically, Asian countries appear most active in UCB-
derived cellular therapy and our analysis of ongoing studies
suggests this trend will likely continue.
Most reported studies infused unprocessed bulk cells
from UCB that was processed and cryopreserved in accor-
dance with standard UCB banking practices. These studies
reported total nucleated cell numbers and other standard
measures of hematopoietic stem cells including CD34þ cell
numbers and colony-forming units. MSCs expanded ex vivo
from freshly collected cells were another cell type reported
commonly in published studies. MSCs were reported in
published trials of tissue regeneration and in studies of
immune dysregulation. Interestingly, recent work suggests
that MSCs can only be expanded successfully from 30% to
60% of UCB units [37], although newer approaches of col-
lecting cells from Wharton’s jelly or from the placenta itself
enhances the yield of MSC expansion from UCB [38].
Although most published reports involved adults, the treat-
ment of adult patients using UCB cells continues to be limited
in part by the total dose of cells per kilogram that can be
delivered from a single unit. Cell losses during processing
and cryopreservation can further reduce the number of
available cells and can limit the ability to culture and expand
MSCs using cryopreserved units [39]. Moreover, the majority
of patients described in published reports received HLA-
compatible cord blood cells or third party MSCs that were
expanded ex vivo. There may be increasing use of autologous
cells in the future, given the presence of autologous cord
blood banking establishments and increasing interest in theTable 4
Cell Types Derived from UCB Used in Treatment for Nonhematopoietic
Diseases
Cell Type Administered Published
(Patients)
Ongoing
Studies, n
TNCs, MNCs, or CD34-selected cells 10 (227) 19
Intravenous (or not stated) 7 (104) 15
Intrathecal, subcutaneous, or intramuscular 3 (123) 4
MSC or cultured adherent cells 8 (88) 24
Intravenous (or not stated) 5 (82) 24
Intrathecal or intramuscular 3 (6) 0
Combined CD34-selected cells and MSCs 2 (2) 4
Intravenous (or not stated) 1 (1) 4
Intrathecal 1 (1) 0
Cell source 20 (317) 47
Allogeneic cells 18 (300) 34
Autologous cells 2 (17) 13
UCB indicates umbilical cord blood; TNC, total nucleated cells; MNC,
mononuclear cells; MSC, mesenchymal stromal cells.area of autologous cord blood transplantation for pediatric
patients with cerebral palsy. The results of ongoing studies
will be informative and will likely shape future directions in
autologous cord blood banking practices.
A limitation of scoping reviews, including ours, is the
possibility that we did not encompass all published and
ongoing trials. We attempted to reduce this error by
searching 3 large scientiﬁc databases (Medline, Embase, and
Cochrane Library) using broad key words and key phrases,
without language restriction. The search results were
double-checked to ensure all relevant studies were identi-
ﬁed. The possibility remains, however, that our search
criteria failed to capture pertinent publications. With regard
to ongoing registered studies identiﬁed using www.clini-
caltrials.gov and the ICTRP of theWorld Health Organization,
it is possible that additional studies were not registered or
were registered with other registries.
In summary, our scoping review provides a synopsis of
the emerging clinical activity in UCB transplantation for
regenerative and immunomodulatory therapy. In addition,
there is increasing activity in the areas of correcting immune
dysregulation that leads to autoimmune disease and
inﬂammatory conditions, and the use of MSCs derived from
UCB is an area of increasing expertise. The United States and
China continue to lead in knowledge generation related to
the use of UCB; however, the extent towhich clinical practice
in these jurisdictions can be applied elsewhere remains to be
examined. Moreover, transplantation into adult patients will
continue with signiﬁcant projected enrollment in ongoing
trials. Regular assessment of published and ongoing activity
in UCB transplantation for emerging novel indications will be
critical for informing UCB banking establishments and
funding agencies to guide changes in banking practices
related to emerging trends in cell therapy.ACKNOWLEDGMENTS
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